



**9 August 2018**

*This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).*

**EKF Diagnostics Holdings plc**  
("EKF", the "Company")

**DiaSpect Tm US distribution agreement with McKesson**

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has signed a private label distribution agreement with McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation – the Fortune Global 500 healthcare distribution specialist and one of the largest companies in the US by revenue – for the Company’s hand-held reagent-free hemoglobin analyzer, the DiaSpect Tm.

The DiaSpect Tm is the world’s fastest hemoglobin analyzer and will be branded in the US by McKesson under its own branded line, as the McKesson Consult® Hb analyzer.

The agreement follows US Food and Drug Administration 510(k) clearance and CLIA waiver by statute for the DiaSpect Tm in April 2018, approving the product for use in point of care and Certificate of Waiver settings. Sales of the McKesson Consult® Hb analyzer are expected following full launch in the autumn, 2018.

For more information on the DiaSpect Tm see: [www.ekfdiagnostics.com/diaspect.html](http://www.ekfdiagnostics.com/diaspect.html)

**Commenting, Julian Baines, CEO of EKF, said:**

*“As I said in April the US market is a key target for the DiaSpect Tm, which gives physicians access to an easy to use, accurate and portable hemoglobin measurement system able to deliver laboratory quality results at the point of care within seconds.”*

*“This agreement with McKesson allows us to offer this innovative technology to physicians and childcare specialists across the US through the market’s leading and most established healthcare distribution player. We expect that this partnership will ultimately deliver significant value to shareholders.”*

**Enquiries:**

**EKF Diagnostics Holdings plc**  
Christopher Mills, Non-Executive Chairman  
Julian Baines, CEO  
Richard Evans, FD & COO

[www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)  
**Tel: 029 2071 0570**

**N+1 Singer (Nomad & Broker)**  
Aubrey Powell / Shaun Dobson

**Tel: 020 7496 3000**

**Walbrook PR Limited**  
Paul McManus / Lianne Cawthorne

**Tel: 020 7933 8780 or [ekf@walbrookpr.com](mailto:ekf@walbrookpr.com)**  
Mob: 07980 541 893 / 07584 391 303

**About McKesson Medical-Surgical [mms.mckesson.com](http://mms.mckesson.com)**

McKesson Medical-Surgical Inc. is an affiliate of the McKesson Corporation. McKesson Corporation, currently ranked 6th on the FORTUNE 500, is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology. McKesson Medical-Surgical works with health systems, physician offices, extended care providers, in-home patients,

labs, payers and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson Medical-Surgical helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services.

**About EKF Diagnostics Holdings plc** [www.ekfdiagnostics.com](http://www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.